HIV-1 immune response

The "HIV-1 immune response" encompasses all arms of host immunity that are activated upon HIV-1 infection, including both innate and adaptive immune responses. Key players are **CD4+ T helper cells**, **CD8+ cytotoxic T lymphocytes (CTLs)**, dendritic cells, natural killer (NK) cells, and B cell–derived antibodies. The HIV-1-specific CTL response is particularly important for early control of viremia, but the virus rapidly escapes by mutation[2][5][7]. Innate defenses include activation of cytokine-mediated antiviral states, dendritic cell activation, and NK cell cytotoxicity[3][6][7]. HIV-1's capacity to rapidly mutate, deplete CD4+ T cells, and avoid immune killing underlies the challenge of durable immune control[2][5]. Since "HIV-1 immune response" is a system property—not a defined molecular target—therapies instead aim to enhance or redirect specific aspects of the response (e.g., CTL vaccines, latent reservoir purging, checkpoint blockade, or chemokine receptor antagonism).

Other names

Immune response to HIV-1Host immune responses in HIV-1 infectionHIV-1-specific immune response